Inhibition of major drug metabolizing CYPs by common herbal medicines used by HIV/AIDS patients in Africa- implications for herb- drug interactions

Drug Metabolism Letters

Volumn 7, Issue 2, 2013, Pages 83-95

  Awortwe, Charles ^a   Bouic, Patrick J ^a,b   Masimirembwa, Collen M ^c   Rosenkranz, Bernd ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b Stellenbosch University Synexa Life Sciences   (South Africa)

^c African Institute of Biomedical Science and Technology   (Zimbabwe)

Author keywords

Cytochrome P450s; Fluorometric assay; Herb drug interactions; Parallel artificial membrane permeability assays

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; ECHINACEA PURPUREA EXTRACT; FLUORESCENT DYE; HYPOXIS HEMEROCALLIDEA EXTRACT; LESSERTIA FRUTESCENS EXTRACT; MORINGA OLEIFERA EXTRACT; PERLAGONIUM SIDOIDES EXTRACT; PLANT EXTRACT; RECOMBINANT ENZYME; TARAXACUM OFFICINALE EXTRACT; UNCLASSIFIED DRUG; ISOENZYME; PLANT MEDICINAL PRODUCT; RECOMBINANT PROTEIN;

AFRICA; AIDS PATIENT; ARTICLE; ARTIFICIAL MEMBRANE; CONTROLLED STUDY; DRUG INHIBITION; DRUG METABOLISM; DRUG SCREENING; ECHINACEA PURPUREA; FOOD AND DRUG ADMINISTRATION; HERB DRUG INTERACTION; HERBAL MEDICINE; HIGH THROUGHPUT SCREENING; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPOXIS; HYPOXIS HEMEROCALLIDEA; IC 50; IN VITRO STUDY; IN VIVO STUDY; LESSERTIA FRUTESCENS; MEDICINAL PLANT; MEMBRANE PERMEABILITY; MORINGA OLEIFERA; NONHUMAN; PERLAGONIUM SIDOIDES; PRACTICE GUIDELINE; PRIORITY JOURNAL; TARAXACUM OFFICINALE; DOSE RESPONSE; ENZYME SPECIFICITY; HIV INFECTIONS; HUMAN; METABOLISM; PHYTOTHERAPY; RISK ASSESSMENT; RISK FACTOR;

AFRICA; ANTI-HIV AGENTS; CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HERB-DRUG INTERACTIONS; HIGH-THROUGHPUT SCREENING ASSAYS; HIV INFECTIONS; HUMANS; ISOENZYMES; PHYTOTHERAPY; PLANT PREPARATIONS; PLANTS, MEDICINAL; RECOMBINANT PROTEINS; RISK ASSESSMENT; RISK FACTORS; SUBSTRATE SPECIFICITY;

EID: 84901808557     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872312808666140129123210     Document Type: Article

References (45)

1. UNAIDS. Collaborating with Traditional Healers for HIV Prevention and Care in Sub-Saharan Africa: Suggestions for Programme Managers and Field Workers. World Health Organization 2007.
2. Verma, S.; Singh, S.P. Current and future status of herbal medicines. Vet World, 2008, 1 (11), 347-350.
3. UNAIDS. Collaborating with traditional healers for HIV prevention and care in sub-Saharan Africa: suggestions for programme managers and field workers, UNAIDS, Geneva 2006.
4. Peltzer, K. An investigation into practices of traditional and faith healers in an urban setting in South Africa. Health SA Gesondheid, 2001, 6, 3-11.
5. Peltzer, K.; Mngqundaniso, N. Patients consulting traditional health practioners in the context of HIV/AIDS in urban areas in KwaZulu- Natal, South Africa. Afr. J. Tradit. Complement. Altern. Med., 2008, 5, 370-379.
6. Obach, R.S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J. Pharmacol. Exp. Ther., 2000, 294, 88-95.
7. Serafini, M.; Stanzione, A.; Foddai, S.; Anton, R.; Delmulle, L. The European role on traditional herbal medicinal products and traditional plant food supplements. J. Clin. Gastroenterol., 2012, 46, S93-4.
8. Mathes, A.; Bellanger, R. Herbs and other dietary supplements: current regulations and recommendations for use to maintain health in the management of the common cold or other related infectious respiratory illnesses. J. Pharm. Pract., 2010, 23(2), 117-27
9. Duggan, J.; Peterson, W.S.; Schutz, M.; Khuder, S; Charkraborty, J. Use of complementary and alternative therapies in HIV-infected patients. AIDS Patient Care STDs, 2001, 15, 159-167.
10. Miller, L. G. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch. Intern. Med., 1998, 158, 2200-2211.
11. Langlois-Klassen, D; Kipp, W; Jhangri, G. S; Rubaale, T. "Use of traditional herbal medicine by AIDS patients in Kabarole District, western Uganda," Am. J. Trop. Med. Hyg., 2007, 77(4), 757-763.
12. Tshibangu, K. C.; Worku, Z. B.; De Jongh, M. A.; Van Wyk, A. E.; Mokwena, S. O.; Peranovic, V. "Assessment of effectiveness of traditional herbal medicine in managing HIV/AIDS patients in South Africa," East Afr. Med. J., 2004, 81 (10), 499-504.
13. Morris K. South Africa tests traditional medicines. Lancet Infect. Dis., 2002, 2, 319.
14. Mills, E.; Cooper, C.; Seely, D.; Kanfer, I. African herbal medicines in the treatment of HIV: Hypoxis and Sutherlandia. An overview of evidence and pharmacology. Nutr. J., 2005, 4, 19.
15. Malangu, N. Self-reported use of traditional, complementary and over-the-counter medicines by HIV-infected patients on antiretroviral therapy in Pretoria, South Africa. Afr. J. Tradit. Complement. Altern. Med., 2007, 4, 273-278.
16. Gallicano, K.; Foster, B.; Choudhri, S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br. J. Clin. Pharmacol., 2003, 55(2), 199-202.
17. de Maat, M.M.R.; Hoetelmans, R.M.W.; Mathôt, R.A.A. Drug interaction between St John's wort and nevirapine. AIDS, 2001, 15, 420-421.
18. Piscitelli, S.C.; Burstein, A.H.; Chaitt, D.; Alfaro, R.M.; Falloon, J. Indinavir concentrations and St John's wort. Lancet, 2001, 14, 357(9263).
19. Clauson, K.A.; Santamarina, M.L.; Rutledge, J.C. Clinically relevant safety issues associated with St. John's wort product labels. BMC Complement. Altern. Med., 2008, 8, 42.
20. Ioannides, C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica, 2002, 32(6), 451-78.
21. Izzo, A.A.; Ernst, E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs, 2009, 69(13), 1777-98.
22. Zhang, L.; Zhang, Y.D.; Zhao, P.; Huang, S.M. Predicting drugdrug interactions: an FDA perspective. AAPS J., 2009, 11(2), 300-6.
23. Modarai, M.; Gertsch, J.; Suter, A.; Heinrich, M.; Kortenkamp, A. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content. J. Pharm. Pharmacol., 2007, 59(4), 567-73.
24. Paine, M.F.; Hart, H.L.; Ludington, S.S.; Haining, R.L.; Rettie, A.E.; Zeldin, D.C. The human intestinal cytochrome P450 "pie." Drug Metab. Dispos., 2006, 34, 880-886.
25. Yang, J.; Tucker, G.T.; Rostami-Hodjegan, A. Cytochrome P450 3A expression and activity in the human small intestine. Clin. Pharmacol. Ther., 2004, 76, 391.
26. Faller, B. Artificial membrane assays to assess permeability. Curr Drug Metab. 2008, 9(9), 886-92.
27. Crespi, C.L.; Miller, V.P.; Penman, B.W. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem., 1997, 248(1), 188-90.
28. Bapiro, T.E.; Egnell, A.C.; Hasler, J.A.; Masimirembwa, C.M. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab. Dispos., 2000, 29(1), 30-5.
29. Thelingwani, R.S.; Zvada, S.P.; Dolgos, H.; Ungell, A.L.; Masimirembwa, C.M. In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions. Drug Metab. Dispos., 2009, 37(6), 1286-94.
30. Yamamoto, T.; Suzuki, A.; Kohno, Y. Application of microtiter plate assay to evaluate inhibitory effects of various compounds on nine cytochrome P450 isoforms and to estimate their inhibitory patterns. Drug Metab. Pharmacokinet., 2002, 17, 437-448.
31. Huang, S.M.; Strong, J.M.; Zhang, L.; Reynolds, K.S.; Nallani, S.; Temple, R. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol., 2008, 48, 662-70.
32. Prueksaritanont, T.; Chu, X.; Gibson, C.; Cui, D.; Yee, K.L.; Ballard, J.; Cabalu, T.; Hochman, J. Drug-drug interaction studies: regulatory guidance and an industry perspective. AAPS J., 2013, 15(3), 629-4.
33. Atkinson, A.; Kenny, J.R.; Grime, K. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab. Dispos., 2005, 33(11), 1637-47.
34. Helsby, N.A.; Chipman, J.K.; Gescher, A.; Kerr, D. Inhibition of mouse and human CYP 1A- and 2E1-dependent substrate metabolism by the isoflavonoids genistein and equol. Food Chem. Toxicol., 1998, 36(5), 375-82.
35. Sai, Y.; Dai, R.; Yang, T.J.; Krausz, K.W.; Gonzalez, F.J.; Gelboin, H.V.; Shou, M. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica, 2000, 30(4), 327-43.
36. Masimirembwa, C.M.; Otter, C.; Berg, M.; Jönsson, M.; Leidvik, B.; Jonsson, E.; Johansson, T.; Bäckman, A.; Edlund, A.; Andersson, T.B. Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research. Drug Metab. Dispos., 1999, 27(10), 1117-22.
37. Fasinu, P.S.; Gutmann, H.; Schiller, H.; Bouic, P.J.; Rosenkranz, B. The potential of Hypoxis hemerocallidea for herb-drug interaction. Pharm. Biol., 2013, 51(12), 1499-507.
38. Fasinu, P.S.; Gutmann, H; Schiller, H; James, A.D.; Bouic, P.J.; Rosenkranz, B. The potential of Sutherlandia frutescens for herbdrug interaction. Drug Metab. Dispos., 2013, 41(2), 488-97
39. Otang, W.M.; Grierson, D.S.; Ndip, R.N. Ethnobotanical survey of medicinal plants used in the management of opportunistic fungal infections in HIV/AIDS patients in the Amathole District of the Eastern Cape Province, South Africa. J. Med. Plants Res., 2012, 6(11), 2071-2080.
40. Yale, S. H.; Glurich, I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J. Altern. Complement. Med., 2005, 11, 433-439.
41. Freeman, C.; Spelman, K. A critical evaluation of drug interactions with Echinacea spp. Mol. Nutr. Food Res., 2008, 52,789-798.
42. Monera, T.G.; Wolfe, A.R.; Maponga C.C.; Benet L.Z.; Guglielmo J. Moringa oleifera leaf extracts inhibit 6β-hydroxylation of testosterone by CYP3A4. J. Infect. Dev. Ctries., 2008, 2(5), 379-383.
43. Mills, E.; Montori, V.; Perri, D.; Phillips, E.; Koren, G. Natural health product-HIV drug interactions: a systematic review. Int. J. STD AIDS, 2005, 16, 181-186.
44. Müller, A.C.; Kanfer, I. Potential pharmacokinetic interactions between antiretrovirals and medicinal plants used as complementary and African traditional medicines. Biopharm. Drug Dispos., 2011, 32(8), 458-70.
45. Shubber, Z.; Calmy, A.; Andrieux-Meyer, I.; Vitoria, M.; Renaud- Théry, F.; Shaffer, N.; Hargreaves, S.; Mills, E.J.; Ford, N. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS, 2013, 27(9), 1403-12.